Show simple item record

dc.contributor.authorMaertens, O
dc.contributor.authorJohnson, B
dc.contributor.authorHollstein, P
dc.contributor.authorFrederick, D
dc.contributor.authorCooper, Z
dc.contributor.authorMessiaen, L
dc.contributor.authorBronson, R
dc.contributor.authorMcMahon, M
dc.contributor.authorGranter, S
dc.contributor.authorFlaherty, K
dc.contributor.authorWargo, J
dc.contributor.authorMarais, Richard
dc.contributor.authorCichowski, K
dc.date.accessioned2013-06-28T15:47:30Z
dc.date.available2013-06-28T15:47:30Z
dc.date.issued2013-03
dc.identifier.citationElucidating distinct roles for NF1 in melanomagenesis. 2013, 3 (3):338-49 Cancer Discoven_GB
dc.identifier.issn2159-8290
dc.identifier.pmid23171796
dc.identifier.doi10.1158/2159-8290.CD-12-0313
dc.identifier.urihttp://hdl.handle.net/10541/294914
dc.description.abstractBRAF mutations play a well-established role in melanomagenesis; however, without additional genetic alterations, tumor development is restricted by oncogene-induced senescence (OIS). Here, we show that mutations in the NF1 tumor suppressor gene cooperate with BRAF mutations in melanomagenesis by preventing OIS. In a genetically engineered mouse model, Nf1 mutations suppress Braf-induced senescence, promote melanocyte hyperproliferation, and enhance melanoma development. Nf1 mutations function by deregulating both phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways. As such, Nf1/Braf-mutant tumors are resistant to BRAF inhibitors but are sensitive to combined inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase and mTOR. Importantly, NF1 is mutated or suppressed in human melanomas that harbor concurrent BRAF mutations, NF1 ablation decreases the sensitivity of melanoma cell lines to BRAF inhibitors, and NF1 is lost in tumors from patients following treatment with these agents. Collectively, these studies provide mechanistic insight into how NF1 cooperates with BRAF mutations in melanoma and show that NF1/neurofibromin inactivation may have an impact on responses to targeted therapies.
dc.language.isoenen
dc.rightsArchived with thanks to Cancer discoveryen_GB
dc.titleElucidating distinct roles for NF1 in melanomagenesis.en
dc.typeArticleen
dc.contributor.departmentGenetics Division, Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts 02115, USA.en_GB
dc.identifier.journalCancer Discoveryen_GB
html.description.abstractBRAF mutations play a well-established role in melanomagenesis; however, without additional genetic alterations, tumor development is restricted by oncogene-induced senescence (OIS). Here, we show that mutations in the NF1 tumor suppressor gene cooperate with BRAF mutations in melanomagenesis by preventing OIS. In a genetically engineered mouse model, Nf1 mutations suppress Braf-induced senescence, promote melanocyte hyperproliferation, and enhance melanoma development. Nf1 mutations function by deregulating both phosphoinositide 3-kinase and extracellular signal-regulated kinase pathways. As such, Nf1/Braf-mutant tumors are resistant to BRAF inhibitors but are sensitive to combined inhibition of mitogen-activated protein/extracellular signal-regulated kinase kinase and mTOR. Importantly, NF1 is mutated or suppressed in human melanomas that harbor concurrent BRAF mutations, NF1 ablation decreases the sensitivity of melanoma cell lines to BRAF inhibitors, and NF1 is lost in tumors from patients following treatment with these agents. Collectively, these studies provide mechanistic insight into how NF1 cooperates with BRAF mutations in melanoma and show that NF1/neurofibromin inactivation may have an impact on responses to targeted therapies.


This item appears in the following Collection(s)

Show simple item record